Related Experiment Videos
Risk factors for adverse cutaneous reactions associated with intravenous vancomycin
T M Korman1, J D Turnidge, M L Grayson
1Department of Infectious Diseases and Microbiology, Monash Medical Centre, Clayton, VIC, Australia.
Abstract:
We retrospectively studied adverse cutaneous reactions associated with intravenous vancomycin therapy over a 14-month period when two different brands of vancomycin were used. Of 224 adults, 12 (5.4%) had infusion-related reactions; ten of 174 patients who received more than one day of vancomycin (5.7%) had delayed cutaneous reactions. Age less than 40 years was a risk factor for both infusion-related and delayed reactions by both univariate and multivariate analysis. Duration of therapy greater than 7 days was a risk factor for delayed reactions. There was a significant increase in adverse cutaneous reactions associated with the use of a particular batch of vancomycin, although analytical testing of this batch failed to identify any difference from other batches associated with routine rates of adverse reactions. Awareness of vancomycin-associated infusion-related and delayed cutaneous reactions is necessary, and the risk factors associated with these reactions may have important clinical implications.
Insights
Adverse cutaneous reactions, including infusion-related and delayed rashes, were observed in patients receiving intravenous vancomycin. Younger age and longer therapy duration were identified as risk factors for these vancomycin side effects.
Area of Science:
- Dermatology
- Pharmacology
- Infectious Diseases
Background:
- Intravenous vancomycin is a critical antibiotic for treating serious Gram-positive bacterial infections.
- Adverse cutaneous reactions are a known complication of vancomycin therapy.
- Understanding the incidence and risk factors for these reactions is crucial for patient safety.
Purpose of the Study:
- To investigate the incidence and characteristics of adverse cutaneous reactions associated with intravenous vancomycin.
- To identify risk factors for both infusion-related and delayed cutaneous reactions.
- To evaluate the impact of different vancomycin brands and batches on reaction rates.
Main Methods:
- Retrospective study design analyzing data from 224 adult patients over 14 months.
- Two different brands of vancomycin were administered during the study period.
- Statistical analysis, including univariate and multivariate analysis, was used to identify risk factors.
Main Results:
- 12 (5.4%) patients experienced infusion-related reactions.
- 10 (5.7%) patients on vancomycin for more than one day had delayed cutaneous reactions.
- Younger age (<40 years) was a significant risk factor for both reaction types.
- Therapy duration >7 days increased the risk of delayed reactions.
- A specific vancomycin batch was associated with a significant increase in reactions, though analytical testing found no differences.
Conclusions:
- Adverse cutaneous reactions, both immediate and delayed, are associated with intravenous vancomycin.
- Younger patients and those on prolonged therapy are at higher risk.
- Clinical vigilance for these reactions and their associated risk factors is essential.
- Further investigation into batch-specific reactions may be warranted despite negative analytical findings.